News | April 30, 2007

CyberHeart to Develop Noninvasive Cardiac Ablation Technique Using Accuray Robotic System

Accuray Inc., a manufacturer of radiosurgery devices, has announced it has entered into an agreement with CyberHeart Inc. under which CyberHeart will use Accuray’s technology to develop a noninvasive method for performing cardiac ablation, which may eventually have applications in the treatment of atrial fibrillation.

Currently cardiac ablation is done during open-heart surgery or as a catheter based procedure in which a catheter is inserted into a blood vessel up to the heart and radiofrequency energy is delivered. Cardiac ablation is most often used to create a lesion that that interferes with abnormal cardiac conduction, with the objective of treating cardiac arrhythmias.

CyberHeart is exploring the use of Accuray’s CyberKnife Robotic Radiosurgery System to generate these lesions noninvasively. The CyberKnife System’s intelligent robotics, accuracy and unique tracking capabilities will be used to target the heart’s affected tissue and create an ablation lesion.

CyberHeart has received commitments for independent venture capital financing to fund technical and clinical research and development of a cardiac ablation system that incorporates Accuray’s technology. In the event CyberHeart is able to successfully develop and commercialize such a system, under Accuray’s agreement with CyberHeart, Accuray will be the sole supplier of radiosurgery equipment to CyberHeart and will also be entitled to receive specified payments based on usage of the CyberHeart system.

According to Accuray, the CyberKnife System represents the next generation of radiosurgery systems, combining continuous image-guidance technology with a compact linear accelerator that has the flexibility to move in three dimensions according to the treatment plan. This combination, which is referred to as intelligent robotics, extends the benefits of radiosurgery to the treatment of tumors anywhere in the body. The CyberKnife System autonomously tracks, detects and corrects for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation typically with sub-millimeter accuracy.

For more information visit www.accuray.com.

Related Content

News | Ablation Systems

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News | Ablation Systems

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the ...

Home May 16, 2019
Home
Subscribe Now